Eric Mou

408 total citations
27 papers, 213 citations indexed

About

Eric Mou is a scholar working on Pathology and Forensic Medicine, Oncology and Epidemiology. According to data from OpenAlex, Eric Mou has authored 27 papers receiving a total of 213 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Pathology and Forensic Medicine, 9 papers in Oncology and 6 papers in Epidemiology. Recurrent topics in Eric Mou's work include Lymphoma Diagnosis and Treatment (15 papers), CAR-T cell therapy research (5 papers) and Cancer Genomics and Diagnostics (5 papers). Eric Mou is often cited by papers focused on Lymphoma Diagnosis and Treatment (15 papers), CAR-T cell therapy research (5 papers) and Cancer Genomics and Diagnostics (5 papers). Eric Mou collaborates with scholars based in United States, France and United Kingdom. Eric Mou's co-authors include Andrew M. Evens, Barbara Pro, Leo I. Gordon, Hatice Savas, Gary Dillehay, Reem Karmali, Pamela B. Allen, Jane N. Winter, Ranjana H. Advani and Joan S. Chmiel and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Eric Mou

23 papers receiving 212 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Eric Mou United States 9 144 104 51 32 32 27 213
Jelena Jelicic Serbia 11 206 1.4× 99 1.0× 66 1.3× 24 0.8× 13 0.4× 38 317
Anna Wall United States 4 180 1.3× 102 1.0× 47 0.9× 35 1.1× 28 0.9× 7 225
P. Brice France 7 164 1.1× 134 1.3× 73 1.4× 107 3.3× 12 0.4× 15 315
Bente Arboe Denmark 7 202 1.4× 123 1.2× 60 1.2× 43 1.3× 15 0.5× 12 279
Maja Bech Juul Denmark 5 167 1.2× 95 0.9× 66 1.3× 22 0.7× 10 0.3× 11 208
Emile D. Kerver Netherlands 7 59 0.4× 74 0.7× 16 0.3× 135 4.2× 11 0.3× 10 238
Samantha Ferrari Italy 4 94 0.7× 76 0.7× 48 0.9× 22 0.7× 5 0.2× 8 218
Stewart Coltart United Kingdom 6 205 1.4× 147 1.4× 88 1.7× 67 2.1× 9 0.3× 7 281
Paolo Avanzini Italy 8 129 0.9× 76 0.7× 51 1.0× 50 1.6× 12 0.4× 24 173
Izumi Wasada Japan 7 263 1.8× 243 2.3× 41 0.8× 17 0.5× 126 3.9× 11 346

Countries citing papers authored by Eric Mou

Since Specialization
Citations

This map shows the geographic impact of Eric Mou's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eric Mou with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eric Mou more than expected).

Fields of papers citing papers by Eric Mou

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eric Mou. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eric Mou. The network helps show where Eric Mou may publish in the future.

Co-authorship network of co-authors of Eric Mou

This figure shows the co-authorship network connecting the top 25 collaborators of Eric Mou. A scholar is included among the top collaborators of Eric Mou based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eric Mou. Eric Mou is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Peña, Tahuanty, et al.. (2024). Chimeric antigen receptor T-cell therapy for refractory post-transplant lymphoproliferative disorder after lung transplantation. SHILAP Revista de lepidopterología. 5. 100101–100101.
3.
Dhakal, Prajwal, et al.. (2024). Overcoming Tagraxofusp-Erzs Monotherapy Resistance in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) in a Real-World Clinical Setting. SHILAP Revista de lepidopterología. 7(3). 205–209. 1 indexed citations
4.
Borcherding, Nicholas, et al.. (2023). Molecular techniques drive cutting edge advancements in management of cutaneous T cell lymphoma. Frontiers in Immunology. 14. 1228563–1228563. 1 indexed citations
5.
Alsawas, Mouaz, et al.. (2023). Sezary syndrome initially presenting as pityriasis rubra pilaris: Clinicopathologic study of 3 cases. JAAD Case Reports. 44. 101–106.
6.
7.
Mwangi, Raphael, Rebecca L. King, Matthew J. Maurer, et al.. (2022). Increasing tissue requirements in lymphoma trials may exclude patients with high-risk disease or worse prognosis. Blood Advances. 6(24). 6180–6186. 1 indexed citations
8.
9.
10.
Rodday, Angie Mae, Susan K. Parsons, Jenica Upshaw, et al.. (2022). The Advanced-Stage Hodgkin Lymphoma International Prognostic Index: Development and Validation of a Clinical Prediction Model From the HoLISTIC Consortium. Journal of Clinical Oncology. 41(11). 2076–2086. 18 indexed citations
11.
Balassanian, Ronald, Matthew C. Cheung, Lorenzo Falchi, et al.. (2021). Global Cytopathology-Hematopathology Practice Trends. American Journal of Clinical Pathology. 157(2). 196–201. 2 indexed citations
12.
Allen, Pamela B., Xinyan Lu, Joan S. Chmiel, et al.. (2021). Frontline Treatment with Single Agent Pembrolizumab (PEM) Followed By AVD Chemotherapy for Classic Hodgkin Lymphoma: Updated Results and Correlative Analysis. Blood. 138(Supplement 1). 231–231. 2 indexed citations
13.
Murphy, Colin, Eric Mou, Emily M. Pang, et al.. (2021). A randomized study of a best practice alert for platelet transfusions. Vox Sanguinis. 117(1). 87–93. 4 indexed citations
14.
Mou, Eric, Ranjana H. Advani, Rie von Eyben, Saul A. Rosenberg, & Richard T. Hoppe. (2020). Long-Term Outcomes of Patients With Early Stage Nonbulky Hodgkin Lymphoma Treated With Combined Modality Therapy in the Stanford V Trials (the G4 and G5 Studies). International Journal of Radiation Oncology*Biology*Physics. 110(2). 444–451. 3 indexed citations
15.
Allen, Pamela B., Hatice Savas, Andrew M. Evens, et al.. (2020). Pembrolizumab followed by AVD in untreated early unfavorable and advanced-stage classical Hodgkin lymphoma. Blood. 137(10). 1318–1326. 84 indexed citations
16.
Mou, Eric, Ilana B. Richman, Andre Kumar, et al.. (2019). Thrombophilia testing in the inpatient setting: impact of an educational intervention. BMC Medical Informatics and Decision Making. 19(1). 167–167. 8 indexed citations
17.
Mou, Eric, Colin Murphy, Jason Hom, Lisa Shieh, & Neil Shah. (2019). Characteristics and Financial Impact of Potentially Inappropriate Platelet Transfusion in the Inpatient Hospital Setting. Blood. 134(Supplement_1). 2096–2096. 1 indexed citations
18.
Jun, Tomi, Eric Mou, Caroline Berube, et al.. (2018). An Electronic Best Practice Alert Based on Choosing Wisely Guidelines Reduces Thrombophilia Testing in the Outpatient Setting. Journal of General Internal Medicine. 34(1). 29–30. 13 indexed citations
19.
Mou, Eric, Lidia Schapira, & P. Kunz. (2018). The Power of Trust. JAMA Oncology. 4(9). 1173–1173. 1 indexed citations
20.
Mou, Eric, Jason Hom, Lisa Shieh, et al.. (2017). Magnitude of Potentially Inappropriate Thrombophilia Testing in the Inpatient Hospital Setting. Journal of Hospital Medicine. 12(9). 735–738. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jelena Jelicic Breakdown of academic impact, for papers by Anna Wall Breakdown of academic impact, for papers by P. Brice Breakdown of academic impact, for papers by Bente Arboe Breakdown of academic impact, for papers by Maja Bech Juul Breakdown of academic impact, for papers by Emile D. Kerver Breakdown of academic impact, for papers by Samantha Ferrari Breakdown of academic impact, for papers by Stewart Coltart Breakdown of academic impact, for papers by Paolo Avanzini Breakdown of academic impact, for papers by Izumi Wasada
Rankless by CCL
2026